home
portfolio
team
careers
contact
investor portal
home
portfolio
team
careers
contact
investor portal
Nextech Invest
EQRx Reports First Quarter 2022 Financial Results and Recent Corporate Progress
EQRx Reports First Quarter 2022 Financial Results and Recent Corporate Progress
Post navigation
Previous Post
Previous
Autolus Therapeutics to Present Four Clinical Data Updates at the European Hematology Association Congress
Next Post
Next
C4 Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating CFT8634, an Orally Bioavailable BiDAC™ Degrader for the Treatment of Synovial Sarcoma and SMARCB1-null Tumors